Vaxcyte, Inc. (NASDAQ: PCVX) announced the successful closing of its underwritten public offering, raising $632.5 million gross proceeds through the sale of 12,650,000 shares of common stock at $50 per share, including the full exercise of underwriters' option for 1,650,000 additional shares. The funds will support the company's clinical-stage vaccine development programs.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine company, announced the pricing of an underwritten public offering of 11 million shares at $50 per share, generating $550 million in gross proceeds. The offering is expected to close on February 2, 2026. The company is developing VAX-31, a 31-valent pneumococcal conjugate vaccine candidate in Phase 3 adult and Phase 2 infant clinical programs, along with other vaccine candidates in its pipeline.

Vaxcyte announced progress on VAX-31, its 31-valent pneumococcal conjugate vaccine, with first participants dosed in the OPUS-2 Phase 3 adult trial evaluating concomitant administration with seasonal influenza vaccine. The company plans to initiate OPUS-3 Phase 3 trial in Q1 2026 for previously vaccinated adults and expects topline data from OPUS-1 in Q4 2026 and OPUS-2/OPUS-3 in H1 2027. For the infant indication, enrollment of 905 participants in the Phase 2 dose-finding study is complete, with data expected by end of H1 2027. Vaxcyte is also establishing manufacturing presence in North Carolina with a planned $1 billion commitment.

Thermo Fisher Scientific is issuing a four-part bond offering in the U.S. investment-grade market, with proceeds intended for general corporate purposes amid potential government shutdown concerns.

The pneumococcal infection market is expected to grow steadily, driven by high global disease burden, rising antimicrobial resistance, and expanded immunization initiatives. Over 15 companies are developing 20+ pipeline therapies, with next-generation vaccines targeting broader serotype coverage.

Vaxcyte reported a wider Q2 2025 net loss of $1.22 per share, driven by increased R&D and G&A expenses. The company advanced its VAX-31 vaccine program with FDA Breakthrough Therapy Designation and has $2.8 billion in cash to fund operations through mid-2028.

Vaxcyte has selected the VAX-24 Mid-dose as the basis for advancing an optimized dose formulation to a potential Phase 3 program. The company plans to initiate an infant Phase 3 study with either VAX-24 or VAX-31 pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026.

Kuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Vaxcyte, Inc. Shareholders may be entitled to damages and corporate governance reforms.

The Vanguard Russell 2000 ETF (VTWO) could be a great investment opportunity in 2025 due to potential benefits from the incoming Trump administration's policies and further interest rate cuts from the Federal Reserve.

Vaxcyte, a vaccine innovation company, announced the pricing of a $1.3 billion public offering of common stock and pre-funded warrants. The offering is expected to close on September 6, 2024.

Vaxcyte, a vaccine innovation company, has announced a $1.0 billion public offering of its common stock and pre-funded warrants. The offering is subject to market conditions and will be used to fund the development of the company's vaccine candidates.

Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate, VAX-31, showed promising results in a Phase 1/2 study, meeting or exceeding the immunogenicity criteria compared to Pfizer's Prevnar 20. Vaxcyte plans to initiate a Phase 3 study by mid-2025.